NCT00352417View on ClinicalTrials.gov

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Atherosclerosis
Interventions
DRUG

VIA-2291

100 mg, oral dosing, 1 time daily for 12 weeks

DRUG

Placebo

oral dosing, 1 time daily for 12 weeks

Trial Locations (3)

Unknown

Azienda Ospedali Riuniti Ancona, Ancona

Presidio Ospedaliero SS Filippo e Nicola, Avezzano

Centro Studi Sull'Invecchiamento, Chieti Scalo

All Listed Sponsors
lead

Tallikut Pharmaceuticals, Inc.

INDUSTRY

NCT00352417 - Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy | Biotech Hunter | Biotech Hunter